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Abstract
Parkinson's disease (PD) is traditionally characterized by the cardinal motor symptoms of tremor,
rigidity, slowness of movement, and impairments of posture, gait, and balance. A relatively new
focus of research and treatment is the nonmotor symptoms of the disease, following from recent
understanding of the neuropathological stages. Disruptions of arousal, mood, sleep, and autonomic
function before the first motor signs of PD implicate the lower brainstem, which is affected before
the substantia nigra and dopaminergic system. In later stages of the disease, the pathology extends
to the cortex, accompanied by impairments in cognition and perception. The articles in this special
section advance our knowledge of the brain bases of the nonmotor symptoms of PD, including
disrupted visual perception, impaired cognition across a range of domains, and psychiatric and
artistic manifestations. Subtypes under investigation include those described by side of disease
onset (left or right body side), predominant cognitive profile, and gender. Taken together, the
articles in this special section reflect the field's growing focus on the nonmotor symptoms of PD,
their brain bases, and the corresponding potential for their treatment.
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Shaking Palsy (Paralysis Agitans): Involuntary tremulous motion, with lessened
muscular power, in parts not in action and even when supported; with a propensity
to bend the trunk forward, and to pass from a walking to a running pace: the senses
and intellects being uninjured (Parkinson, 2002, p. 223).
This description opens the first chapter of James Parkinson's (1817/2002) classic
monograph, “An Essay on the Shaking Palsy.” In keeping with his initial description,
Parkinson's disease (PD) today is characterized by the cardinal motor symptoms of resting
tremor; rigidity; akinesia or bradykinesia (slowness of movement); impairments of posture,
gait, and balance; as well as motor abnormalities such as dyskinesias. The diagnosis,
according to the widely used U.K. Parkinson's Disease Society Brain Bank Clinical
Diagnostic Criteria (Hughes, Daniel, Kilford, & Lees, 1992), requires only the motor
symptoms of bradykinesia and muscular rigidity, tremor, or postural instability. Other
supportive prospective positive criteria include unilateral onset and persistent asymmetry,
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progressive disorder, course of 10+ years, and response to levodopa—all of these linked
closely with the motor symptoms.
In a departure from the traditional view, the nonmotor symptoms of PD have been receiving
increasing attention in recent years. Examples of these symptoms include disturbances of
cognition, sensation and perception, mood, motivation, behavioral inhibition, sleep, and
autonomic function. In his essay, Parkinson described certain common nonmotor signs in
individual patients, including autonomic and sleep disruption (though he attributed the latter
to tremor). The nonmotor symptoms are prevalent: It is rare to find a patient who does not
suffer from one or more. They are troublesome: Patients often cite them as more detrimental
to quality of life than the motor symptoms (Chaudhuri, Odin, Antonini, & Martinez-Martin,
2011; Sjödahl Hammarlund, Hagell, & Nilsson, 2012). They vary tremendously in type and
in when they appear during the disease course. Much remains to be learned about the
etiology, clinical presentation, course, treatment, and neurological substrates of these
dysfunctions, the existence of which belies the traditional view of PD as exclusively a
“movement disorder.”
To what should we attribute the rising interest in the nonmotor components of the disease?
In many respects, it is unsatisfying to researchers and clinicians to focus on symptoms for
which there is no clear mechanism of action. James Parkinson did not know the etiology of
any aspect of the disease—he certainly did not mention the substantia nigra or dopamine—
but he did offer the following: “Supposed proximate cause: A diseased state of the medulla
spinalis, in that part which is contained in the canal, formed by the superior cervical
vertebrae, and extending, as the disease proceeds, to the medulla oblongata” (Parkinson,
2002, p. 230). Dysfunction of the medulla and other lower brainstem areas, such as the locus
ceruleus and raphé nuclei, could account for a number of nonmotor symptoms, including
changes in arousal, mood, and autonomic function, but Parkinson's implication of the lower
brainstem in the development of the disease seems to have fallen by the historical wayside—
certainly by the time of the discovery of the death of dopamine-producing neurons in the
substantia nigra, and the subsequent success of levodopa as a treatment for the motor
symptoms of PD. The clinical and research emphasis on the substantia nigra and dopamine
resulted in a decades-long focus of attention on this neurotransmitter in regard to PD
etiology and treatment (reviewed in Goetz, 2011). Unfortunately, dopaminergic treatment
does not relieve the nonmotor symptoms of the disease, and relatively little progress was
made during this period in understanding what causes these symptoms, much less how to
treat them. Chaudhuri and colleagues (2011) have memorably referred to the lack of
consideration of treatments of nonmotor symptoms as “therapeutic nihilism.”
The past decade, however, has witnessed a refocusing of attention on the lower brainstem
and its potential contributions to the nonmotor symptoms of PD. This refocusing has
followed from the publication of articles by Braak and colleagues on the neuropathological
staging of PD, relating symptoms to synucleinopathy (density of Lewy bodies and Lewy
neurites) in various brain regions over the course of the disease. Besides the olfactory bulbs,
lower brainstem areas—including the medulla oblongata (as proposed by Parkinson)—
appear to be affected first, well before the substantia nigra. As described by Braak,
Ghebremedhin, Rüb, Bratzke, & Del Tredici (2004, p. 129):
It is important to bear in mind that during the first two stages, the pathology in
nonolfactory sites is confined to the medulla oblongata and pontine tegmentum.
Thus, the process that ultimately leads to the full clinical picture of PD does not
have, as its point of departure, the substantia nigra… On the contrary, the
involvement of the substantia nigra presupposes the existence of an obvious
pathology in the medulla oblongata. Indeed, were it to become possible to diagnose
PD in the presymptomatic stages 1 or 2, and were a causal therapy to become
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available, the subsequent neuronal loss in the substantia nigra could be entirely
prevented.
There is mounting evidence of disruptions in the domains of arousal, mood, sleep, and
autonomic function before the first motor signs of PD, suggesting the existence of a
prodromal phase (“presymptomatic,” according to Braak and colleagues; e.g., Chaudhuri et
al., 2011; Gaenslen, Swid, Liepelt-Scarfone, Godau, & Berg, 2011; Gaig & Tolosa, 2009;
Jacob, Gatto, Thompson, Bordelon, & Ritz, 2010; Postuma et al., 2012). The terms
prodromal or presymptomatic refer to symptoms that manifest before the appearance of the
motor symptoms that have always defined the disease. In the later stages (Braak stages 5 and
6), the pathology extends to the cortex: “Inclusion bodies appear first in the prefrontal and
high-order sensory association areas of the neocortex (stage 5)…, then in the premotor and
first-order sensory association areas, and, finally, in some instances, even in the primary
fields (stage 6)…” (Braak et al., 2004).
The cortical pathology as evidenced by the presence of the Lewy inclusion bodies and by
cortical thinning, such as that reported for orbitofrontal cortex, ventrolateral prefrontal
cortex, and occipitoparietal areas—including the unimodal visual cortex (Tinaz, Courtney,
& Stern, 2011)—is accompanied by the expected symptoms in cognition and perception,
though these seem not to have been noticed by Parkinson himself (“the senses and intellects
being uninjured”). For a helpful depiction of the nonmotor symptoms that may be associated
with each Braak stage, see the review by Gaenslen and colleagues (2011).
It is reasonable to attribute the fast growth of research on the nonmotor symptoms of PD to
the proposed neuropathological etiologies of nonmotor symptoms, together with the inability
of current treatments to adequately address these symptoms. Besides being a disease that
afflicts a great number of people and attracts clinicians and researchers who specialize in
prevention and treatment, PD is also a “problem” that accommodates the interest of a wide
range of neuroscientists, from geneticists to psychologists. Additionally, as is true for many
brain disorders, studying PD gives us valuable insights into the structure and function of the
normal brain (e.g., see Martinu & Monchi, this issue, pp. 222–236, on cerebrobasal ganglia
and cerebrocerebellar circuitry). Further, the fact that PD is a heterogeneous disorder in
regard to symptomatology (motor and nonmotor) alerts us to the possibility of subtypes.
Subtypes that are currently being studied in the field include, among others, those described
by side of disease onset or side of current symptom predominance (reviewed in Cronin-
Golomb, 2010), type of initial motor symptom (e.g., tremor, rigidity, disturbances of posture
and gait), predominant cognitive profile (nondementia or dementia; or frontal-type vs.
posterior-type, the latter as discussed by Miller and colleagues, this issue, pp. 175–183),
presence or absence of specific genes (e.g., parkin, LRRK2, COMT, MAPT), and gender
(reviewed in Miller & Cronin-Golomb, 2010).
The articles included in this special section on PD broadly advance our knowledge of
nonmotor systems involved in the disease, including those supporting visual perception,
cognition across a range of domains (touching on both mild cognitive impairment and
specific cognitive disturbances in nondemented patients), as well as psychiatric and even
artistic manifestations. Each of the articles discusses aspects of brain dysfunction relevant to
the nonmotor symptom in question, including cortical and subcortical brain regions as well
as sensory periphery (e.g., retina). The order of the articles reflects the general topic areas,
with adjacent articles speaking to each other on various levels.
There are two articles on visual perception. The first, by Bodis-Wollner, Glazman, and
Yerram (this issue, pp. 139–150), is a review of aspects of known visual disturbance in PD.
We are especially gratified to have Dr. Bodis-Wollner's contribution, as he initiated research
on PD vision beginning in the 1970s, being among the first to convincingly show the error
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of James Parkinson's statement in his original essay about the “senses … being uninjured.”
Besides describing visual abnormalities, this article raises the question as to what extent
retinal dysfunction contributes to visuospatial disturbances in PD. The relation of retinal and
cortical deficits to high-order visuospatial function is addressed in the article by Laudate,
Neargarder, and Cronin-Golomb (this issue, pp. 151–163), using multiple methods to
establish potential sources of hemifield viewing bias in PD (left vs. right disease onset),
including analysis of the thickness of the retinal nerve fiber layer with optical coherence
tomography (OCT), analysis of retinal function with frequency doubling technology (FDT),
and eye tracking.
Next, there are several articles representing research on a wide range of cognitive domains,
including attention and executive function, social cognition, emotion recognition, and
learning and memory. Attentional disturbance is addressed by Smith, Geissler, Schallert, and
Lee (this issue, pp. 164–174), specifically the inability in PD to disengage from one activity
and attend to another. This group studied rats in the examination of the central amygdala,
which receives nigral dopamine input, and provides evidence for its role in the modulation
of disengagement behavior. The importance of this article lies in the implication of
subcortical (amygdalar) pathology in the development of a deficit in what is usually thought
of as a higher-order cognitive function; if amygdalar pathology precedes cortical pathology,
then this sort of attentional disturbance may appear in patients well before the later Braak
stages of disease. Offering some support for this idea, Miller, Neargarder, Risi, and Cronin-
Golomb (this issue, pp. 175–183) report that measures of attention are more sensitive to
differences between patients with mild to moderate PD and healthy adults than are
neuropsychological tests from most other cognitive domains. This finding is relevant to
growing concerns about mild cognitive impairment in PD and the ability to diagnose it early
in the disease course. In the realm of social cognition, Anderson, Simpson, Channon,
Samuel, and Brown (this issue, pp. 184–192) found disturbances only in PD patients with
mild cognitive impairment, whereas those without mild cognitive impairment performed
normally. These investigators did, however, note that even the latter type of patient may
experience anxiety in social situations, and suggested that this social anxiety could arise
from multiple causes, such as from nondopaminergic pathology associated with anxiety or
from cognitive biases as often seen in social phobia. The next article, by Buxton,
MacDonald, and Tippett (this issue, pp. 193– 203), provides an alternative potential basis for
social difficulties by describing patients' impairments in recognizing subtle expressions of
emotion. In regard to learning and memory, Schendan, Tinaz, Maher, and Stern (this issue,
pp. 204–221) used behavioral measures and functional neuroimaging to show changes in
frontostriatal and medial temporal-lobe activation patterns associated with reduced spatial
sequence learning. Further consideration of motor sequence learning and motor adaptation
(the ability to compensate for changing environments) is provided in the review by Martinu
and Monchi (this issue, pp. 222–236), in particular in regard to corticobasal ganglia and
corticocerebellar circuitry, respectively. These authors raise the question as to whether the
corticocerebellar circuit is recruited in PD to compensate for corticobasal ganglia
dysfunction or, instead, whether observed changes in cerebellar activity in PD arise from
pathophysiological changes resulting from the disease itself. This broad review of motor and
nonmotor disturbances incorporates discussions of anatomy, functional circuitry, PD
pathology, metabolic and functional changes, and effects of dopaminergic medications and
deep brain stimulation as treatments for PD.
The final section is on psychiatric and artistic manifestations of PD. Saez-Francas,
Hernández-Vara, Roso, Martín, and Brugué (this issue, pp. 237–244) provide a
consideration of apathy in PD and the extent of its independence from central fatigue, which
is a feeling of constant exhaustion and difficulty in initiating or sustaining voluntary
activities. A key to understanding apathy is that it is not a single construct; the domains of
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intellectual curiosity and action initiation are related to fatigue, unlike the domains of
emotion and self-awareness. The investigators found effects of subtypes, including by side
of symptom severity and by gender, calling for more subtype research. On the other end of
the initiation spectrum from apathy are impulse control disorders, also referred to as
behavioral addictions or impulsive-compulsive behaviors (ICBs). ICBs occur in a subset of
PD patients, often in association with treatment with dopamine agonists. Averbeck,
Djamshidian, O'Sullivan, Housden, Roiser, and Lees (this issue, pp. 245–255) consolidated
data from three studies of ICBs and developed a model to account for reward-guided
behavior across the various tasks. Specifically, those with ICBs behave as if they are unable
to use contextual information to inform future actions. Finally, Inzelberg (this issue, pp.
256–261) provides a provocative review of the postmedication development of artistic
creativity in PD. Although this artistic development seems to be dependent on treatment
exposure, it is not usually associated with ICBs, indicating that the relation between creative
drive and dopamine dysregulation is not straightforward.
In summary, whereas research and clinical work has traditionally focused on the defining
motor features of PD, the current movement in the field is toward an inclusive understanding
of the nonmotor symptoms. This special section reflects the growing focus on these
nonmotor symptoms, their brain bases, and the attendant potential for their treatment.
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